CYBB Knockout HL-60 Cell Line

The choice depends on whether you are studying CYBB (gp91phox, NOX2)'s role as the catalytic membrane subunit of the phagocyte NADPH oxidase or modeling chronic granulomatous disease (CGD). The Knockout line is the standard tool for asking whether NOX2 is required for the phagocyte respiratory burst — CYBB is the principal membrane subunit of the NOX2 NADPH oxidase complex (with CYBA/p22phox, NCF1/p47phox, NCF2/p67phox, NCF4/p40phox, and Rac1/2), generating superoxide for pathogen killing in neutrophils, macrophages, and microglia. Overexpression is useful for studying CYBB gain-of-function effects. For phagocyte biology and CGD research, the EDITGENE CYBB Knockout in HL-60 is uniquely valuable — HL-60 is a human promyelocytic leukemia cell line that can be differentiated into neutrophil-like cells (DMSO, ATRA induction), providing the gold-standard genetic null model for phagocyte respiratory burst studies. CYBB X-linked recessive mutations cause X-linked CGD (the most common CGD form, ~70% of cases), characterized by recurrent bacterial/fungal infections and granuloma formation. Rescue with wild-type or patient-derived CYBB mutations enables disease genotype-function studies. The knockout is valuable for studying NOX2 biology, X-CGD disease modeling, and emerging therapeutic strategies including gene therapy (CYBB gene therapy clinical trials have shown promising results).

Primary applications: • Respiratory burst: superoxide production (DHE, lucigenin chemiluminescence) and reactive oxygen species (DCF-DA) analysis following PMA, fMLF, or pathogen stimulation in differentiated HL-60 cells. • CGD modeling: rescue with patient-derived CYBB mutations (e.g., truncation/missense mutations from X-CGD patients) for genotype-function studies. • Phagocyte killing assays: bacterial/fungal killing assays given the requirement for NOX2-mediated superoxide production for microbicidal activity. • CGD gene therapy validation: critical genetic null background for testing CYBB gene therapy vectors (clinical trials have shown promising results for X-CGD gene therapy). EDITGENE recommends this differentiated HL-60-based model as the gold-standard human genetic null for X-CGD disease modeling, NOX2 biology, and CYBB gene therapy validation.

Yes. CYBB rescue experiments are well-established for CGD research: • Construct design: use a codon-modified CYBB sequence with a small intracellular C-terminal tag (FLAG, HA). CYBB/gp91phox is a six-transmembrane domain protein with N-terminal heme-binding, FAD-binding, and NADPH-binding regions — preserve membrane topology. • Surface/membrane localization validation: confirm proper membrane localization before respiratory burst assays. • Partner subunit considerations: NOX2 complex assembly requires CYBA/p22phox, NCF1/p47phox, NCF2/p67phox, NCF4/p40phox, Rac1/2 — rescue interpretation considers these subunit levels. • X-CGD patient mutation rescue: rescue with patient-derived CYBB mutations (missense, splice, truncation) enables disease genotype-function studies and gene therapy vector validation. • Functional readout: rescue should restore PMA-induced superoxide production measured by lucigenin chemiluminescence or DHE oxidation in differentiated HL-60 cells. HL-60-specific considerations: • HL-60 is a human acute promyelocytic leukemia cell line that can be induced to differentiate into neutrophil-like (DMSO, ATRA induction) or monocyte/macrophage-like (PMA, vitamin D3 induction) cells — widely used for myeloid biology, neutrophil function, and CGD research. • Lentiviral transduction is moderately efficient; characterize differentiation state and myeloid markers before phenotypic assays. • HL-60 neutrophil-like differentiation enables study of NADPH oxidase respiratory burst, which is the canonical CYBB function.